Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Belimumab safely improved renal function in lupus nephritis patients

Publish date:: June 19, 2020

Key clinical point: Treatment with belimumab on top of standard systemic lupus erythematosus therapy safely improved renal function during 2 years on treatment compared with patients who did not receive the drug.

Major finding: After 2 years, the primary endpoint renal response occurred in 43% who received belimumab and 32% of control patients .

Study details: BLISS-LN, a multicenter, randomized trial with 446 evaluable patients.

Disclosures: BLISS-LN was sponsored by GlaxoSmithKline, the company that markets belimumab (Benlysta). Dr. Furie is a consultant to and has received research funding from GlaxoSmithKline, and several of the study’s coauthors are employees of the company.

Citation:

Furie RA et al. Ann Rheum Dis. 2020 Jun;79[suppl 1]:103, Abstract OP0164.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Nephrology

Dapagliflozin’s CKD performance sends heart failure messages,

DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use,

Survival after kidney transplantation lags in diabetes patients,

DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes,

Belimumab safely improved renal function in lupus nephritis patients,